Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer

Asian Cardiovascular and Thoracic Annals

Volumn 14, Issue 2, 2006, Pages 139-144

  Park, Inkyu ^a   Chung, Kyung Young ^a   Kim, Kil Dong ^b   Kim, Dae Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Eulji University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

UFT;

ADULT; AGE; AGED; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INDIGESTION; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PLEURA EFFUSION; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VOMITING;

EID: 33646182419     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230601400212     Document Type: Review

References (21)

1. Ambrogi V, Pompeo E, Elia S, Pistolese GR, Mineo TC. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardio-thorac Surg 2003;23:811-7.
2. Ponn RB, LoCicero J III, Daly BD. Surgical treatment of non-small cell lung cancer. In: Shields TW, LoCicero J III, Ponn RB, Rusch VW, editors. General thoracic surgery. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2004:1548-87.
3. Martini N. Surgical treatment of non-small cell lung cancer by stage. Semin Surg Oncol 1990;6:248-54.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 2005;352:2589-97.
7. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996;14:1048-54.
8. Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998;14:256-64.
9. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.
10. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
11. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with Sobin LH and pathologists from 14 countries. Histological typing of lung and pleural tumors. World Health Organization. International histological classification of tumors. 3rd ed. Berlin: Springer-Verlag, 1999.
12. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96.
13. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer An analysis in each pathologic stage. J Thorac Cadiovasc Surg 1995;110:601-5.
14. Manac'h D, Riquet M, Medioni J, Le Pimpec-Barthes F, Dujon A, Danel C. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 2001;71:1088-93.
15. Osaki T, Nagashima A, Yoshimatsu T, Yamada S, Yasumoto K. Visceral pleural involvement in nonsmall cell lung cancer: prognostic significance. Ann Thorac Surg 2004:77:1769-73.
16. Shimizu K, Yoshida J, Nagai K, Nishimura M, Yokose T, Ishii G, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg 2004;127:1574-8.
17. Kim K, Chung K, Hong K, Kim D. The surgical results of stage I lung cancer. Korean J Thorac Cardiovasc Surg 1998;31:982-7.
18. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
19. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72.
20. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-East Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003;40:181-6.
21. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-7.